Catalog No.
Product Name
Application
Product Information
Citations
-
E3 ligase ligand-linker conjugate
Pomalidomide-PEG4-Ph-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology. -
ligand-linker conjugate
CCK2R Ligand-Linker Conjugates 1 is a ligand-linker conjugate, which conjugates to the cytotoxic antimicrotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) via a hydrophilic peptide linker. -
Lenalidomide-based Cereblon ligand
Lenalidomide-C5-NH2 is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-C5-NH2 can be connected to the ligand for protein by a linker to form PROTACs. - VH032-thiol-C6-NH2 (VHL Ligand-Linker Conjugates 14) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.
- Pomalidomide-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.
-
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-C4-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-C8-NH2 TFA (Cereblon Ligand -Linker Conjugates 2 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-C4-NH2 TFA (Cereblon Ligand-Linker Conjugates 6 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-PEG3-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology. - (S,R,S)-AHPC-(C3-?PEG)?2-?C6-?Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker. (S,R,S)-AHPC-(C3-?PEG)?2-?C6-?Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.
-
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology. - (S,R,S)-AHPC-PEG6-C4-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 6-unit PEG linker. (S,R,S)-AHPC-PEG6-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.
- Thalidomide-O-amido-C8-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
-
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG4-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG1-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 1-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-C3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Pomalidomide-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Pomalidomide-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C6-NH2 is a synthesized E3 ligase ligand-linker conjugate, featuring a Thalidomide-based cereblon ligand integrated with a flexible linker tailored for PROTAC (Proteolysis Targeting Chimera) applications. This compound demonstrates the capacity to facilitate targeted protein degradation by recruiting E3 ligases to specific substrates, thereby enhancing the control of protein levels in cellular systems. It is valuable for research in targeted therapy and protein regulation studies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-NH-PEG1-COOH TFA functions as an E3 Ligase Ligand-Linker Conjugate that targets Cereblon (CRBN). This compound selectively recruits the CRBN protein, facilitating targeted protein degradation pathways. Thalidomide-4-NH-PEG1-COOH TFA is a critical intermediate in the synthesis of CRBN-based PROTAC molecules, making it valuable for research into novel therapeutic strategies in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG1-C2-NH2 is an E3 ligase ligand-linker conjugate designed for use in targeted protein degradation applications. This compound features a Thalidomide-derived cereblon ligand that facilitates the recruitment of specific substrates to the ubiquitin-proteasome system. Its linker component is compatible with PROTAC technology, making it a valuable tool for researchers investigating therapeutic strategies aimed at modulating protein levels within cells. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C8-NH2 is a synthetic E3 ligase ligand-linker conjugate that features a Thalidomide-based cereblon ligand. This compound serves as a valuable tool in PROTAC (Proteolysis Targeting Chimera) technology, facilitating targeted degradation of specific proteins in cellular systems. It is widely utilized in studies focusing on protein homeostasis, disease modeling, and therapeutic development in various fields including cancer research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C8-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that combines the Thalidomide-derived cereblon ligand with a C8 amido linker. This compound is specifically designed for use in PROTAC technology, facilitating targeted protein degradation by recruiting E3 ligases to specific substrates. Its biochemical properties make it suitable for investigating protein modulation and therapeutic applications in cellular research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG2-C2-NH2 is a conjugate designed for E3 ligase targeting, featuring a Thalidomide-derived cereblon ligand combined with a polyethylene glycol (PEG) linker. This compound facilitates targeted protein degradation by engaging E3 ligases through PROTAC technology. It is suitable for research applications aimed at exploring protein regulation and therapeutic interventions in various diseases. -
E3 ligase ligand-Linker Conjugate
Thalidomide-NH-PEG1-NH2 is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a polyethylene glycol (PEG) linker, designed for proteolysis-targeting chimera (PROTAC) applications. This compound facilitates the recruitment of E3 ligases, enabling targeted degradation of specific proteins within cellular environments. It is instrumental in the development of novel therapeutic strategies for modulating protein levels in research studies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG4-Boc is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a PEG4 linker. This compound is designed for use in PROTAC technology, facilitating targeted protein degradation. It exhibits key biological activity by modulating the E3 ligase pathways, making it a valuable tool in the study of protein homeostasis and therapeutic applications in disease models. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amide-C5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that targets cereblon via its Thalidomide component. This compound is designed for use in PROTAC (proteolysis-targeting chimeras) technology, facilitating the targeted degradation of specific proteins within various biological pathways. Its application in chemical research allows for enhanced studies in protein regulation and therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C2-NH2 is a synthetic E3 ligase ligand-linker conjugate designed to target cereblon, a substrate receptor for the ubiquitin-proteasome system. This compound plays a crucial role in PROTAC technology, facilitating targeted protein degradation by linking a specific protein of interest to the E3 ligase for ubiquitination. Its application enhances the study of protein function and regulation in cellular processes, making it valuable for research in drug development and disease modulation. -
E3 ligase ligand-Linker Conjugate
Thalidomide-NH-PEG1-NH2 diTFA is a synthesized E3 ligase ligand-linker conjugate designed to target cereblon, a substrate receptor for the E3 ubiquitin ligase complex. This compound facilitates the development of PROTAC (proteolysis-targeting chimera) technology, enabling targeted protein degradation in various biological research applications. Its unique structure is instrumental in studying protein interactions and modulation within cellular pathways. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG3-C2-NH2 is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound features a cereblon ligand derived from Thalidomide, coupled with a PEG3 linker, facilitating the development of proteolysis-targeting chimeras (PROTACs). Its primary utility lies in modulating protein levels within cellular systems, enabling researchers to investigate protein function and potential therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C8-NH2 is a synthesized E3 ligase ligand-linker conjugate that targets cereblon through its Thalidomide-derived component. This compound is designed for applications in PROTAC technology, facilitating targeted protein degradation. Its structure combines a specific ligand with a functional linker, making it a valuable tool for research in cellular signaling and protein modulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-PEG8-Ts is a synthesized E3 ligase ligand-linker conjugate that combines the Thalidomide-derived cereblon ligand with an eight-unit polyethylene glycol (PEG) linker. This compound is essential in the development of PROTAC (Proteolysis Targeting Chimeras) technology, enabling targeted degradation of specific proteins through the recruitment of E3 ligases. Its applications include research in targeted protein degradation, with potential implications in various therapeutic areas, including cancer and neurodegenerative diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG4-amine TFA is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a PEG4 linker for use in proteolysis-targeting chimera (PROTAC) applications. This compound facilitates targeted protein degradation by promoting the interaction between E3 ligases and specific substrate proteins. It serves as a valuable tool for researchers investigating cellular protein regulation and therapeutic interventions in various disease models. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG1-C2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate designed to incorporate a thalidomide-based cereblon ligand with a polyethylene glycol (PEG) linker. This compound facilitates targeted protein degradation through PROTAC technology, enhancing specificity and efficacy in research applications. It serves as a valuable tool for studying the role of E3 ligases in cellular processes and for developing novel therapeutic strategies through targeted modulation of protein levels. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that features a thalidomide-derived cereblon ligand. This reagent plays a crucial role in PROTAC (proteolysis-targeting chimeras) technology, facilitating targeted protein degradation. It is of significant interest in drug discovery and development research, particularly for studies aimed at modulating protein function and enhancing therapeutic efficacy. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-C4-NH2 is an E3 ligase ligand-linker conjugate featuring a cereblon ligand derived from thalidomide, combined with a linker utilized in PROTAC technology. This compound is designed to selectively recruit E3 ligases for targeted protein degradation, making it valuable for studies in targeted therapy and drug development. It facilitates the exploration of protein dynamics and functions, contributing to advancements in cancer research and other diseases linked to protein misregulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG2-C2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that features a thalidomide-derived cereblon ligand. This compound is designed to facilitate targeted protein degradation through PROTAC technology, enabling researchers to study protein interactions and dysregulation in various biological contexts. Its unique structure supports the development of novel therapeutic strategies by harnessing the ubiquitin-proteasome system for selective protein modulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C5-NH2 is an E3 ligase ligand-linker conjugate that utilizes the cereblon ligand derived from Thalidomide, combined with a linker suitable for targeted protein degradation applications. This compound facilitates the design of PROTAC molecules, enabling the selective degradation of target proteins via the ubiquitin-proteasome pathway. Its function in research may enhance studies related to therapeutic modalities in cancer and other diseases through targeted protein regulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that targets cereblon, an E3 ubiquitin ligase. This compound is designed for use in PROTAC technology, enabling targeted protein degradation and facilitating the selective modulation of protein levels in cellular systems. It is suitable for research applications focused on protein homeostasis and therapeutic development for various diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C3-NH2 is an E3 ligase ligand-linker conjugate that integrates a thalidomide-derived cereblon ligand with a flexible linker designed for use in PROTAC (proteolysis-targeting chimera) technology. This compound facilitates the targeted ubiquitination and subsequent degradation of specific proteins, thereby allowing researchers to investigate protein function and regulation. Its applications extend to drug discovery and development, particularly in therapies targeting diseases driven by protein misfolding or dysregulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-NH-PEG1-NH2 TFA is an E3 ligase ligand-linker conjugate that targets Cereblon (CRBN). This compound serves as a critical ligand to recruit the CRBN protein, facilitating the development of proteolysis-targeting chimeras (PROTACs). It plays a significant role in studies focused on targeted protein degradation and E3 ligase modulation in biochemical and pharmacological research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C7-acid is a synthesized E3 ligase ligand-linker conjugate that utilizes the cereblon ligand derived from Thalidomide. This compound serves as a vital component in the development of PROTAC (proteolysis-targeting chimeras) technology, enabling targeted protein degradation. Thalidomide-O-C7-acid is instrumental for researchers focusing on protein regulation and therapeutic applications in various disease models. -
E3 Ligase Ligand-Linker Conjugate
Deoxy-thalidomide-Pip-C-PIP-boc is a conjugate that functions as an E3 ligase ligand-linker complex, featuring Thalidomide as a critical component. This compound acts as a Cereblon ligand, facilitating the recruitment of the CRBN protein, which is essential for targeted protein degradation. It serves as a vital intermediate in the synthesis of complete PROTAC (Proteolysis Targeting Chimeras) molecules, making it valuable for research in targeted therapeutic strategies and protein homeostasis. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-PIP-(R)C-pyrrolidine-boc is a conjugate that acts as an E3 ligase ligand-linker complex, incorporating Thalidomide as the enabling component. This compound functions as a Cereblon ligand, facilitating the recruitment of the CRBN protein and serving as a crucial intermediate in the synthesis of PROTAC molecules. Its role in targeted protein degradation makes it a valuable tool for addressing complex biological questions in chemical biology and therapeutic development.
